Sarita Dubey

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson, Ross C. Donehower, S. Tjulandin et al. · The Lancet Oncology · 2014 · 260 citations

Gastrointestinal Oncology, Medicine, Pathology +8

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

Sumanta K. Pal, Robert G. Uzzo, José A. Karam et al. · The Lancet · 2022 · 214 citations · Full text

Surgical Oncology, Urology, Genitourinary Cancer +9

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Robert J. Motzer, Thomas Powles, Michael B. Atkins et al. · JAMA Oncology · 2021 · 155 citations · Full text

Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study

Anne M. Traynor, Sarita Dubey, Jens C. Eickhoff et al. · Journal of Thoracic Oncology · 2009 · 139 citations · Full text

Tumor Biology, Medicine, Cancer Management +6

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

Sarita Dubey, Pasi A. Jänne, Lee M. Krug et al. · Journal of Thoracic Oncology · 2010 · 115 citations

Hematological Malignancy, Malignant Disease, Malignant Mesothelioma +8